Would you offer immunotherapy in addition to chemotherapy and trastuzumab for patients with metastatic HER2-positive gastroesophageal cancer with low PDL1?

As of August 26, 2026, this question has become moot: trastuzumab has been replaced in the first-line setting by the FDA approval of zanidatamab, a bispecific/biparatopic antibody against two epitopes of HER2. Approval was based on the results of the HERIZON-GEA-01 study, which randomized patients t...